Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.
Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  2. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  3. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  4. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  7. Ximerakis M, et al. 2023. Nat Aging. 3:327. PubMed
  8. Liao Y, et al. 2023. ACS Omega. 8:15217. PubMed
  9. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  10. Liu JC, et al. 2023. Int J Mol Sci. 24:. PubMed
  11. Tang L, et al. 2023. Front Immunol. 14:1145441. PubMed
  12. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  13. Malik JR, et al. 2023. Int J Mol Sci. 24:. PubMed
  14. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  15. Komoto S, et al. 2023. Cancers (Basel). 15:. PubMed
  16. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  17. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  18. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  19. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  20. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  21. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  22. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  23. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  24. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  25. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  26. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  27. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  28. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  29. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  30. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  31. Healy LM, et al. 2020. Glia. 68:811. PubMed
  32. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  33. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  34. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  35. Herz J, et al. 2021. Neuron. 109:3609. PubMed
  36. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  37. Miek L, et al. 2022. Immunology. 166:47. PubMed
  38. Wolf B, et al. 2022. Immunology. 166:380. PubMed
  39. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  40. Shcheynikov N, et al. 2022. Hepatology. 76:1248. PubMed
  41. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  42. Adam-Artigues A, et al. 2022. Sci Adv. 8:eabk2746. PubMed
  43. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  44. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  45. Ma T, et al. 2022. Elife. 11: . PubMed
  46. Benedetti V, et al. 2022. Sci Adv. 8:eabn3986. PubMed
  47. Guasconi L, et al. 2022. J Fungi (Basel). 8: . PubMed
  48. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  49. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  50. Martínez-Sabadell A, et al. 2022. Cell Rep. 41:111430. PubMed
  51. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  52. Dhar R, et al. 2022. Int J Mol Med. 50: . PubMed
  53. Balood M, et al. 2022. Nature. 611:405. PubMed
  54. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  55. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  56. Rico-Llanos G, et al. 2022. Front Immunol. 13:1054962. PubMed
  57. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  58. Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed
  59. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  60. Pleuger C, et al. 2022. Elife. 11: . PubMed
  61. Shen W, et al. 2023. Dis Model Mech. 16: . PubMed
  62. Perveen R, et al. 2023. Hum Cell. 36:583. PubMed
  63. Krammer S, et al. 2022. Cells. 12: . PubMed
  64. Chan L, et al. 2022. Cells. 12: . PubMed
  65. Cousin N, et al. 2022. Cells. 12: . PubMed
  66. Rice CM, et al. 2023. Life Sci Alliance. 6: . PubMed
  67. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  68. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  69. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  70. Gong HH, et al. 2023. Front Immunol. 13:1089064. PubMed
  71. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  72. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  73. Li H, et al. 2023. Front Immunol. 13:1056447. PubMed
  74. Lutz EA, et al. 2022. PNAS Nexus. 1:pgac244. PubMed
  75. Badenes M, et al. 2023. Life Sci Alliance. 6: . PubMed
  76. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  77. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  78. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  79. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  80. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  81. Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed
  82. Ryan CB, et al. 2022. Neurobiol Dis. 163:105608. PubMed
  83. Fahrner JE, et al. 2022. Cancer Discov. 12:958. PubMed
  84. Blair TC, et al. 2022. Life Sci Alliance. 5:. PubMed
  85. Ko J, et al. 2022. Nat Biotechnol. 40:1654. PubMed
  86. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  87. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  88. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  89. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  90. Frost JN, et al. 2022. Sci Adv. 8:eabq5384. PubMed
  91. Schuhmacher J, et al. 2022. Cells. 11:. PubMed
  92. Cruz-Reséndiz A, et al. 2022. Front Immunol. 13:1057499. PubMed
  93. Johnson SD, et al. 2022. Front Immunol. 13:1001727. PubMed
  94. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  95. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  96. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  97. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  98. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  99. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  100. Fernandes S, et al. 2023. iScience. 26:106071. PubMed
  101. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  102. Medina S, et al. 2023. Water (Basel). 15:. PubMed
  103. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  104. Xu K, et al. 2023. Elife. 12:. PubMed
  105. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  106. Zhang J, et al. 2023. Front Immunol. 14:1091541. PubMed
  107. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  108. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  109. Ahmed O, et al. 2023. Bioelectron Med. 9:6. PubMed
  110. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
  111. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  112. Madar J, et al. 2023. Nat Commun. 14:2158. PubMed
  113. Consonni FM, et al. 2023. Front Immunol. 14:1168455. PubMed
  114. Fang Y, et al. 2023. Front Immunol. 14:1162004. PubMed
  115. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  116. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  117. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  118. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  119. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  120. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  121. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  122. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  123. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  124. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  125. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  126. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  127. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  128. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  129. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  130. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  131. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  132. Price P, et al. 2014. J Virol. 88:10840. PubMed
  133. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  134. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  135. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  136. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  137. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  138. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  139. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  140. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  141. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  142. Toomer G, et al. 2022. Viruses. 14:. PubMed
  143. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  144. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  145. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  146. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  147. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  148. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  149. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  150. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  151. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  152. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  153. Munoz MA, et al. 2021. Elife. 10:. PubMed
  154. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  155. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  156. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  157. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  158. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  159. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  160. Yu X, et al. 2021. Nature. 594:560. PubMed
  161. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  162. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  163. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  164. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  165. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  166. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  167. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  168. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  169. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  170. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  171. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  172. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  173. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  174. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  175. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  176. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  177. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  178. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  179. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  180. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  181. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  182. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  183. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  184. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  185. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  186. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  187. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  188. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  189. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  190. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  191. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  192. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  193. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  194. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  195. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  196. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  197. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  198. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  199. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  200. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  201. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  202. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  203. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  204. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  205. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  206. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  207. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  208. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  209. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  210. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  211. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  212. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  213. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  214. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  215. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  216. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  217. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  218. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  219. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  220. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  221. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  222. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  223. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  224. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  225. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  226. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  227. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  228. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  229. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  230. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  231. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  232. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  233. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  234. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  235. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  236. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  237. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  238. Romine KA, et al. 2021. Cancer Discov. . PubMed
  239. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  240. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  241. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  242. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  243. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  244. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  245. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  246. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  247. Köchl R, et al. 2020. Elife. 9:00. PubMed
  248. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  249. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  250. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  251. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  252. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  253. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  254. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  255. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  256. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  257. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  258. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  259. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  260. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  261. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  262. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  263. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  264. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  265. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  266. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  267. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  268. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  269. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  270. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  271. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  272. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  273. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  274. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  275. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  276. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  277. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  278. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  279. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  280. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  281. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  282. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  283. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  284. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  285. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  286. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  287. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  288. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  289. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  290. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  291. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  292. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  293. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  294. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  295. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  296. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  297. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  298. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  299. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  300. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  301. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  302. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  303. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  304. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  305. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  306. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  307. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  308. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  309. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  310. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  311. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  312. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  313. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  314. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  315. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  316. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  317. Barington L, et al. 2022. Cells. 11:. PubMed
  318. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  319. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  320. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  321. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  322. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  323. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  324. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  325. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  326. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  327. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  328. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  329. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  330. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  331. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  332. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  333. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  334. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  335. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  336. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  337. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  338. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  339. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  340. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  341. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  342. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  343. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  344. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  345. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  346. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  347. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  348. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  349. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  350. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  351. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  352. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  353. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  354. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  355. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  356. Kumar S, et al. 2022. Gut. . PubMed
  357. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  358. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  359. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  360. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  361. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  362. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  363. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  364. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  365. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  366. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  367. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  368. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  369. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  370. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  371. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  372. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  373. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  374. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  375. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  376. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  377. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  378. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  379. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  380. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  381. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  382. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  383. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  384. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  385. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  386. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  387. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  388. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  389. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  390. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  391. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  392. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  393. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  394. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  395. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  396. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  397. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  398. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  399. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  400. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  401. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  402. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  403. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  404. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  405. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  406. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  407. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  408. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  409. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  410. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  411. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  412. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  413. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  414. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  415. Yuan C, et al. 2018. iScience. 11:13. PubMed
  416. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  417. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  418. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  419. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  420. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  421. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  422. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  423. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  424. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  425. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  426. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  427. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  428. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  429. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  430. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  431. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  432. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  433. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  434. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  435. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  436. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  437. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  438. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  439. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  440. Spath S, et al. 2022. iScience. 25:104998. PubMed
  441. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  442. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  443. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  444. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  445. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  446. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  447. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  448. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  449. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  450. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  451. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  452. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  453. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  454. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  455. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  456. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  457. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  458. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  459. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  460. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  461. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 9    Revision Date: 12.18.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account